Cutler Group’s IGM Biosciences IGMS Stock Holding History

Cutler Group’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-39,500	Closed	-$68K	–	5277
2022 Q1	$68K	Buy	39,500 +39,100	+9,775%	+$728K	﹤0.01%	1993
2021 Q4	$2K	Buy	+400	New	+$19.9K	﹤0.01%	4749

Other funds holding IGMS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Cutler Group's IGMS Position: Q4 2023 in Review

Cutler Group sold out of IGM Biosciences (IGMS) in Q4 2023, closing a stake of 400 shares — an estimated $3K sold.

Cutler Group first reported a position in IGMS in Q1 2022 and held it in 4 quarters. The position peaked at $18K in Q1 2022. 72 funds tracked by Wall St. Rank hold IGMS as of Q4 2023.

Cutler Group reported no remaining IGM Biosciences position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 400 IGM Biosciences shares in Q4 2023, an estimated $3K.
Cutler Group first reported a position in IGM Biosciences in Q1 2022 and held it in 4 quarters.
Cutler Group's IGM Biosciences position peaked at $18K in Q1 2022.
72 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.